Imaging Recommendations for Diagnosis, Staging, and Management of Cervical Cancer

Abstract Cervical cancer is the fourth most common cancer in women globally and the second most common cancer in Indian women, more common in lower socioeconomic strata. Improvement in survival and decrease in morbidity reflect the earlier detection with screening and imaging, as well as multifactorial multimodality therapy integrating surgery, and concurrent chemoradiation therapy providing superior therapeutic benefits. Imaging plays a vital role in assessing the extent of disease and staging of cervical cancer. The appropriateness criteria of a modality are different from its availability based on infrastructure, medical facilities, and resource status. Although in an ideal situation, magnetic resonance imaging (MRI) would be of greatest value in locoregional assessment of extent of disease and fluorodeoxyglucose positron emission tomography-computed tomography for distant staging; often, an ultrasonography, chest radiograph, and bone scans are utilized, with contrast-enhanced computed tomography representing a fair superior diagnostic accuracy, and can be reported as per the RECIST 1.1 criteria. MRI is also of good utility in the assessment of residual disease, predicting response and detecting small volume recurrence. MRI offers the highest diagnostic accuracy in determining parametrial invasion and hence surgical planning; so also, MRI-guided radiation planning helps in more accurate graded radiation dose planning in radiation therapy. Stage and therapy-based surveillance imaging should be encouraged and recommended.

[1]  E. Zubizarreta,et al.  Point-A vs. Volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  C. Kirisits,et al.  MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. , 2021, The Lancet. Oncology.

[3]  M. Washington,et al.  The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer , 2021, CA: a cancer journal for clinicians.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  T. Stokke,et al.  MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer , 2020, Cancer Research.

[6]  D. Dong,et al.  Multi-Habitat Based Radiomics for the Prediction of Treatment Response to Concurrent Chemotherapy and Radiation Therapy in Locally Advanced Cervical Cancer , 2020, Frontiers in Oncology.

[7]  B. Monk,et al.  Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Haldorsen,et al.  What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer? , 2019, Current Oncology Reports.

[9]  J. Berek,et al.  Revised FIGO staging for carcinoma of the cervix uteri , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  M. Thakur,et al.  National Cancer Grid of India Consensus Guidelines on the Management of Cervical Cancer , 2018, Journal of global oncology.

[11]  R. Pötter,et al.  The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer , 2018, International Journal of Gynecologic Cancer.

[12]  M. Thakur,et al.  Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Thakur,et al.  Magnetic Resonance Imaging of Gynecological Malignancies: Role in Personalized Management. , 2017, Seminars in ultrasound, CT, and MR.

[14]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[15]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[16]  T. Kasamatsu,et al.  Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[18]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christian Kirisits,et al.  Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  D. Cella,et al.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[23]  B N Bundy,et al.  A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. , 1999, Gynecologic oncology.